Supernus Pharmaceuticals, Inc.
SUPN
$48.27
$1.122.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -2,445.62% | 44.14% | 90.90% | -300.53% | 290.23% |
| Total Depreciation and Amortization | -1.47% | 4.46% | 0.85% | 16.14% | 4.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 46.20% | -58.39% | 541.10% | 146.30% | -60.85% |
| Change in Net Operating Assets | -112.81% | 142.36% | -4.38% | -528.12% | -17.36% |
| Cash from Operations | -107.23% | 234.95% | 132.21% | -205.35% | 91.30% |
| Capital Expenditure | -- | -- | -231.01% | 71.65% | -39.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 139.87% | 62.23% | -114.88% | 1,234.01% | -180.10% |
| Cash from Investing | 136.91% | 62.55% | -205.35% | 259.13% | -182.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -69.84% | 59.75% | -63.96% | 624.69% | 60.43% |
| Repurchase of Common Stock | 98.07% | -14,593.55% | 96.18% | -1,663.04% | 98.62% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 18.87% | 88.58% |
| Cash from Financing | -178.99% | 6.91% | -59.53% | 2,153.26% | 104.37% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -108.71% | 346.13% | -382.65% | -71.90% | -37.95% |